GSTP1 Ile105Val Polymorphism and Prostate Cancer Risk: Evidence from a Meta-Analysis

Abstract

BackgroundGlutathione S-transferase P1 (GSTP1) is thought to be involved in the detoxification of reactive carcinogen metabolites. Numerous epidemiological studies have evaluated the association of GSTP1 Ile105Val polymorphism with the risk of prostate cancer. However, the results remain inconclusive. To derive a more precise estimation, a meta-analysis was performed.Methodology/Principal FindingsA comprehensive search was conducted to identify the eligible studies. We used odds ratios (ORs) with 95% confidence intervals (CIs) to assess the strength of the relationship. The overall association was not significant (Val/Val vs. Ile/Ile OR = 1.06, 95% CI = 0.90–1.25, P = 0.50; Val/Val vs. Val/Ile+Ile/Ile: OR = 1.07, 95% CI = 0.91–1.25, P = 0.44). In subgroup analyses by ethnicity and prostate cancer grade, the similar results were observed. However, in stratified analysis by clinical stage, we found a significant association with low-stage prostate cancer (Val/Val vs. Ile/Ile: OR = 2.70, 95% CI = 1.73–4.22, P<0.001; Val/Val vs. Val/Ile+Ile/Ile: OR = 2.14, 95% CI = 1.38–3.33, P = 0.001). Moreover, there was no statistically significant evidence of multiplicative interactions neither between the GSTP1 Ile105Val polymorphism and GSTM1, nor between smoking status and GSTP1 on prostate cancer risk.ConclusionsThis meta-analysis showed that GSTP1 Ile105Val polymorphism might not be significantly associated with overall prostate cancer risk. Further stratified analyses showed a significant association with low-stage prostate cancer.

Interaction between GSTT1 and GSTP1 allele variants as a risk modulating-factor for autism spectrum disorders

“…Another study by Aynacioglu et al (2004) reported that the Val/Val homozygous genotype appeared to be somewhat protective against developing asthma compared to the other two genotypes (Aynacioglu, Nacak, Filiz, Ekinci, & Roots, 2004). A recessive model of GSTP1 was used in a study by Wei et al (Wei et al, 2013), where a significant association was found for low-stage prostate cancer in a meta-analysis. A dominant model was considered by Chen et al (2010) and a significant association of GSTP1 with hepatocellular carcinoma was observed (Chen et al, 2010).…”

“…Several of the GST family subgroup genes, including GST mu 1 ( GSTM1 ), GST pi 1 ( GSTP1 ), and GST theta 1 ( GSTT1 ), are highly polymorphic (Loktionov et al, 2001). Sequence variation in these genes has also been associated with an increased or decreased risk for several cancers and chronic diseases, including colorectal cancer (Loktionov et al, 2001), esophageal cancer (Sharma et al, 2013), renal cell carcinoma (Cheng, You, & Zhou, 2012; Yang et al, 2013), acute leukemia (Ye & Song, 2005), prostate cancer (Harries, Stubbins, Forman, Howard, & Wolf, 1997; Kote-Jarai et al, 2001; Liu, Liu, Ran, Shang, & Li, 2013; Safarinejad, Shafiei, & Safarinejad, 2011; Taioli et al, 2011; Wei et al, 2013), type-2 diabetes mellitus (Dadbinpour, Sheikhha, Darbouy, & Afkhami-Ardekani, 2013; Ramprasath et al, 2011), asthma (Tamer et al, 2004), and neurodevelopmental disorders such as ASD (Buyske et al, 2006). The variants in GSTM1 and GSTT1 examined here are insertion-deletion polymorphisms, and the homozygous deletions or null genotypes indicate that activities or functionality of these genes are reduced or interrupted completely (Ye, Song, Higgins, Pharoah, & Danesh, 2006).…”

“…For the GSTP1 Ile105Val polymorphism, there are three common genotypes (Ile/Val, Ile/Ile, Val/Val), and the replacement of adenine by guanine at nucleotide 562 results in the change of amino acid from isoleucine to valine at codon 105 of the GSTP1 protein. Researchers have used different classifications (e.g., co-dominant, recessive, dominant, and additive models) for a variety of disease association studies (Ramprasath et al, 2011; Safarinejad et al, 2011; Sreeja et al, 2008; Tamer et al, 2004; Wei et al, 2013). The frequency of the GSTP1 polymorphism varies across different populations, as shown in the International Haplotype Map (HapMap) project (The International HapMap Consortium, 2003).…”

The Relation between Polymorphisms in Exon 5 and Exon 6 of GSTP1 Gene and the Risk of Lung Cancer in Iranian People

“…Epidemiological studies have confirmed that those who express different types of GSTP1 alleles are less susceptible to various types of carcinogenic agents (Josephy, 2010;Andreoli and Sprovieri, 2017). Recent studies have reported the relation between GSTP1 Val105 polymorphism and other types of cancers, including prostate (Wei et al, 2013), breast (Louie et al, 2016), and bladder cancers (Yu et al, 2016).…”

Involvement of Cytochrome P450 1A1 and Glutathione S-Transferase P1 Polymorphisms and Promoter Hypermethylation in the Progression of Anti-Tuberculosis Drug-Induced Liver Injury: A Case–Control Study

“…In general, individuals with the CYP2E1 C1/C1 genotype, slow acetylator NAT2 genotype, or GSTM1 null genotype have been shown to have an increased risk of ADLI [ 20 , 21 ]. In addition, studies have shown the Ile105Val and MspI polymorphisms in GSTP1 and CYP1A1 , respectively, with mutant genotypes likely reducing the activities of the respective genes [ 22 , 23 ]. However, we found GSTP1 and CYP1A1 polymorphisms to be unrelated to increased risk of ADLI.…”